LCD L38125: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies — Noridian
Policy LCD-L38125 · Oncology
New LCD for myeloid malignancies requires billing team review.
Code intelligence
D46.0 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code D46.0.
Normal code riskView ICD-10 detail
Signal breakdown
2 shown · 2 total in platform
Risk: Normal
0
Critical
0%
0
High
0%
2
Routine
100%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
LCD L40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — CGS
Policy LCD-L40000 · Hematology
New LCD impacts billing for myeloproliferative neoplasms testing.
Audit documentation
Building an audit file that includes D46.0?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription